论文部分内容阅读
[目的]研究罗格列酮对胰岛素抵抗者的抵抗素基因表达水平的影响。[方法]将胰岛素抵抗患者的单个核细胞、单核源性巨噬细胞分别分为罗格列酮干预组(n=8)和对照组(n=8)。分别采用实时荧光定量PCR法、配对t检验检测、比较干预组和对照组细胞的抵抗素基因表达水平。[结果]罗格列酮干预组的单核源性巨噬细胞的抵抗素基因表达水平显著低于对照组(3.23±1.34vs0.94±1.22,t=3.565;P=0.009),两组单个核细胞的抵抗素基因表达水平无统计学差异。[结论]罗格列酮可以降低胰岛素抵抗者的单核源性巨噬细胞的抵抗素基因表达水平。罗格列酮可能是通过降低胰岛素抵抗患者的促炎症细胞因子水平而调控其炎症状况。
[Objective] To study the effect of rosiglitazone on resistin gene expression in insulin resistance. [Methods] Mononuclear cells and monocyte-derived macrophages from patients with insulin resistance were divided into two groups: rosiglitazone intervention group (n = 8) and control group (n = 8). Respectively using real-time fluorescence quantitative PCR method, paired t test to detect the resistin gene expression levels in the intervention group and control group cells. [Results] The level of resistin gene expression in monocyte-derived macrophages in rosiglitazone-treated group was significantly lower than that in control group (3.23 ± 1.34 vs 0.94 ± 1.22, t = 3.565; P = 0.009) There was no statistical difference in the expression of resistin gene in nuclear cells. [Conclusion] Rosiglitazone can reduce the resistin gene expression in monocyte-derived macrophages of insulin resistance. Rosiglitazone may regulate its inflammatory status by decreasing the level of proinflammatory cytokines in patients with insulin resistance.